The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer-Reference-Cited by-同舟云学术

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer

Published:2018-06 Issue:6 Volume:13 Page:792-800
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lee Chee Khoon,Lord Sally,Marschner Ian,Wu Yi Long,Sequist Lecia,Rosell Rafael,Fukuoka Masahiro,Mitsudomi Tetsuya,Asher Rebecca,Davies Lucy,Gebski Val,Gralla Richard,Mok Tony,Yang James Chih-Hsin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Gefitinib or erlotinib vs. chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival;Lee;J Natl Cancer Inst,2017

2. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol,2015

3. Measuring the clinical response. What does it mean?;Therasse;Eur J Cancer,2002

4. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann Oncol,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway;Journal of Pharmacy and Pharmacology;2024-01-18

2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

3. The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status;Cancer Reports;2021-11-12

4. A Model-Strengthened Imaging Biomarker for Survival Prediction in EGFR-Mutated Non-small-cell Lung Carcinoma Patients Treated with Tyrosine Kinase Inhibitors;Bulletin of Mathematical Biology;2021-05-08

5. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment;European Journal of Cancer;2021-05